Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imagin...( New imaging modality highlights Volca...)

New imaging modality highlights Volcano commitment to intravascular imaging

and opens up new clinical and research applications

SAN DIEGO and BRUSSELS, Belgium, May 8 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today the first human procedure using the Volcano OCT Imaging catheter. The procedure was performed by Dr. Patrick Serruys at the Thoraxcenter, in Rotterdam, Netherlands. Volcano OCT will complement its existing line of IVUS imaging catheters and pressure guidewires used for coronary imaging and lesion assessment.

Volcano acquired the OCT technology through its purchase of CardioSpectra at the end of 2007.

Scott Huennekens, President and Chief Executive Officer of Volcano, commented, "Volcano is committed to being the leader in intravascular imaging, both to complement everyday PCI technique, and to further the understanding of atherosclerotic disease progression. Our investment in this OCT product line underscores that commitment, and opens a series of new clinical applications and opportunities to complement our existing product line. We are delighted to be underway with our OCT effort just four months after completing the acquisition.

"With our two imaging technologies, we are the leader in intravascular imaging and commercializing this technology will provide us further competitive advantages. We are working on offerings that incorporate OCT functionality into our s5i IVUS platform, as well as standalone OCT systems. Our emph
'/>"/>